Carbetocin vs. Oxytocin for Preventing Postpartum Hemorrhage in High-Risk C-Sections

Postpartum Hemorrhage (PPH) is a leading cause of maternal mortality worldwide, often resulting from uterine atony (failure of the uterus to contract after childbirth). Women undergoing Caesarean sections (CS), especially those with placenta previa (where the placenta covers the cervix), face a significantly elevated risk of PPH. While Oxytocin is the standard uterotonic agent used to prevent PPH, a newer synthetic analog, Carbetocin, offers a longer duration of action. This study addresses the critical knowledge gap of which uterotonic agent is more effective in preventing PPH in high-risk CS cases like placenta previa.

As this record describes a study protocol (NCT02303418) rather than a completed research paper, specific quantitative results are not yet available. The researchers' primary objective is to rigorously compare the incidence of atonic PPH, the total amount of blood loss (measured in milliliters), and the requirement for additional uterotonic agents between the Carbetocin and Oxytocin treatment arms. They will also meticulously assess uterine tone and the immediate need for further intervention 2 minutes following drug administration, providing an early indicator of efficacy. > The most critical finding expected from this Phase 3 trial will be the definitive quantitative comparison of Carbetocin versus Oxytocin in reducing the occurrence of PPH in women undergoing Caesarean sections for placenta previa. Future publications will detail precise data, such as the percentage reduction in PPH rates, average blood loss volumes, and the proportion of women requiring rescue therapies in each group, offering crucial insights for clinical decision-making.